143 related articles for article (PubMed ID: 10372563)
1. Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells.
Rundfeldt C
Epilepsy Res; 1999 Jun; 35(2):99-107. PubMed ID: 10372563
[TBL] [Abstract][Full Text] [Related]
2. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
Main MJ; Cryan JE; Dupere JR; Cox B; Clare JJ; Burbidge SA
Mol Pharmacol; 2000 Aug; 58(2):253-62. PubMed ID: 10908292
[TBL] [Abstract][Full Text] [Related]
3. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.
Wickenden AD; Yu W; Zou A; Jegla T; Wagoner PK
Mol Pharmacol; 2000 Sep; 58(3):591-600. PubMed ID: 10953053
[TBL] [Abstract][Full Text] [Related]
4. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells.
Rundfeldt C
Eur J Pharmacol; 1997 Oct; 336(2-3):243-9. PubMed ID: 9384239
[TBL] [Abstract][Full Text] [Related]
5. The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation.
Dost R; Rundfeldt C
Epilepsy Res; 2000 Jan; 38(1):53-66. PubMed ID: 10604606
[TBL] [Abstract][Full Text] [Related]
6. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits.
Rundfeldt C; Netzer R
Neurosci Lett; 2000 Mar; 282(1-2):73-6. PubMed ID: 10713399
[TBL] [Abstract][Full Text] [Related]
7. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices.
Armand V; Rundfeldt C; Heinemann U
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jan; 359(1):33-9. PubMed ID: 9933148
[TBL] [Abstract][Full Text] [Related]
8. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels.
Rundfeldt C; Netzer R
Arzneimittelforschung; 2000 Dec; 50(12):1063-70. PubMed ID: 11190770
[TBL] [Abstract][Full Text] [Related]
9. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.
Dost R; Rostock A; Rundfeldt C
Naunyn Schmiedebergs Arch Pharmacol; 2004 Apr; 369(4):382-90. PubMed ID: 15007538
[TBL] [Abstract][Full Text] [Related]
10. KCNQ4 channel activation by BMS-204352 and retigabine.
Schrøder RL; Jespersen T; Christophersen P; Strøbaek D; Jensen BS; Olesen SP
Neuropharmacology; 2001 Jun; 40(7):888-98. PubMed ID: 11378159
[TBL] [Abstract][Full Text] [Related]
11. Activation of KCNQ channels located on the skeletal muscle membrane by retigabine and its influence on the maximal muscle force in rat muscle strips.
Zagorchev P; Apostolova E; Kokova V; Peychev L
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):439-46. PubMed ID: 26815201
[TBL] [Abstract][Full Text] [Related]
12. The anticonvulsant retigabine suppresses neuronal K
Stas JI; Bocksteins E; Jensen CS; Schmitt N; Snyders DJ
Sci Rep; 2016 Oct; 6():35080. PubMed ID: 27734968
[TBL] [Abstract][Full Text] [Related]
13. Retigabine strongly reduces repetitive firing in rat entorhinal cortex.
Hetka R; Rundfeldt C; Heinemann U; Schmitz D
Eur J Pharmacol; 1999 Dec; 386(2-3):165-71. PubMed ID: 10618466
[TBL] [Abstract][Full Text] [Related]
14. Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels.
Lange W; Geissendörfer J; Schenzer A; Grötzinger J; Seebohm G; Friedrich T; Schwake M
Mol Pharmacol; 2009 Feb; 75(2):272-80. PubMed ID: 19015229
[TBL] [Abstract][Full Text] [Related]
15. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate.
Wuttke TV; Seebohm G; Bail S; Maljevic S; Lerche H
Mol Pharmacol; 2005 Apr; 67(4):1009-17. PubMed ID: 15662042
[TBL] [Abstract][Full Text] [Related]
16. Kv7/KCNQ/M-channels in rat glutamatergic hippocampal axons and their role in regulation of excitability and transmitter release.
Vervaeke K; Gu N; Agdestein C; Hu H; Storm JF
J Physiol; 2006 Oct; 576(Pt 1):235-56. PubMed ID: 16840518
[TBL] [Abstract][Full Text] [Related]
17. Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells.
Tatulian L; Brown DA
J Physiol; 2003 May; 549(Pt 1):57-63. PubMed ID: 12702739
[TBL] [Abstract][Full Text] [Related]
18. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Gunthorpe MJ; Large CH; Sankar R
Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
[TBL] [Abstract][Full Text] [Related]
19. Retigabine, a K(V)7 (KCNQ) potassium channel opener, attenuates L-DOPA-induced dyskinesias in 6-OHDA-lesioned rats.
Sander SE; Lemm C; Lange N; Hamann M; Richter A
Neuropharmacology; 2012 Feb; 62(2):1052-61. PubMed ID: 22079161
[TBL] [Abstract][Full Text] [Related]
20. Functional up-regulation of the M-current by retigabine contrasts hyperexcitability and excitotoxicity on rat hypoglossal motoneurons.
Ghezzi F; Monni L; Nistri A
J Physiol; 2018 Jul; 596(13):2611-2629. PubMed ID: 29736957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
